Cell and gene therapies for refractory epilepsy

被引:33
作者
Boison, Detlev [1 ]
机构
[1] Legacy Res, Robert Stone Neurobiol Labs, Portland, OR 97232 USA
关键词
epilepsy; epileptogenesis; cell therapy; gene therapy; GABA; adenosine; galanin; neuropeptide Y; EMBRYONIC STEM-CELLS; NEUROPEPTIDE-Y RECEPTOR; CENTRAL PIRIFORM CORTEX; NUCLEOSIDE TRANSPORTER FAMILY; HIPPOCAMPAL DENTATE GYRUS; SIMPLEX-VIRUS VECTORS; ADENOSINE KINASE; STATUS EPILEPTICUS; BONE-MARROW; IN-VIVO;
D O I
10.2174/157015907780866938
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Despite recent advances in the development of antiepileptic drugs, refractory epilepsy remains a major clinical problem affecting up to 35% of patients with partial epilepsy. Currently, there are few therapies that affect the underlying disease process. Therefore, novel therapeutic concepts are urgently needed. The recent development of experimental cell and gene therapies may offer several advantages compared to conventional systemic pharmacotherapy: (i) Specificity to underlying pathogenetic mechanisms by rational design; (ii) specificity to epileptogenic networks by focal delivery; and (in) avoidance of side effects. A number of naturally occurring brain substances, such as GABA, adenosine, and the neuropepticles galanin and neuropeptide Y, may function as endogenous anticonvulsants and, in addition, may interact with the process ofepileptogenesis. Unfortunately, the systemic application of these compounds is compromised by limited bioavailability, poor penetration of the blood-brain barrier, or the widespread systemic distribution of their respective receptors. Therefore, in recent years a new field of cell and gene-based neuropharmacology has emerged, aimed at either delivering endogenous anticonvulsant compounds by focal intracerebral transplantation of bioengineered cells (ex vivo gene therapy), or by inducing epileptogenic brain areas to produce these compounds in situ (in vivo gene therapy). In this review, recent efforts to develop GABA-, adenosine-, galanin-, and neuropeptide Y- based cell and gene therapies are discussed. The neurochemical rationales for using these Compounds are discussed, the advantages of focal' applications are highlighted and preclinical cell transplantation and gene therapy studies are critically evaluated. Although many promising data have been generated recently, potential problems, such as long-term therapeutic efficacy, long-term safety, and efficacy in clinically relevant animal models, need to be addressed before clinical applications can be contemplated.
引用
收藏
页码:115 / 125
页数:11
相关论文
共 178 条
  • [1] Gene therapy for amyotrophic lateral sclerosis (ALS) using a polymer encapsulated xenogenic cell line engineered to secrete hCNTF
    Aebischer, P
    Pochon, NAM
    Heyd, B
    Deglon, N
    Joseph, JM
    Zurn, AD
    Baetge, EE
    Hammang, JP
    Goddard, M
    Lysaght, M
    Kaplan, F
    Kato, AC
    Schluep, M
    Hirt, L
    Regli, F
    Porchet, F
    DeTribolet, N
    [J]. HUMAN GENE THERAPY, 1996, 7 (07) : 851 - 860
  • [2] TRANSPLANTATION IN HUMANS OF ENCAPSULATED XENOGENEIC CELLS WITHOUT IMMUNOSUPPRESSION - A PRELIMINARY-REPORT
    AEBISCHER, P
    BUCHSER, E
    JOSEPH, JM
    FAVRE, J
    DETRIBOLET, N
    LYSAGHT, M
    RUDNICK, S
    GODDARD, M
    [J]. TRANSPLANTATION, 1994, 58 (11) : 1275 - 1277
  • [3] Baekelandt V, 2000, CURR OPIN MOL THER, V2, P540
  • [4] The equilibrative nucleoside transporter family, SLC29
    Baldwin, SA
    Beal, PR
    Yao, SYM
    King, AE
    Cass, CE
    Young, JD
    [J]. PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY, 2004, 447 (05): : 735 - 743
  • [5] Neuropeptide Y and epilepsy: recent progress, prospects and controversies
    Baraban, SC
    [J]. NEUROPEPTIDES, 2004, 38 (04) : 261 - 265
  • [6] Antiepileptic actions of neuropeptide Y in the mouse hippocampus require Y5 receptors
    Baraban, SC
    [J]. EPILEPSIA, 2002, 43 : 9 - 13
  • [7] Immune Problems in Central Nervous System Cell Therapy
    Barker R.A.
    Widner H.
    [J]. NeuroRX, 2004, 1 (4): : 472 - 481
  • [8] Mesenchymal stem cells: clinical applications and biological characterization
    Barry, FP
    Murphy, JM
    [J]. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2004, 36 (04) : 568 - 584
  • [9] Human epilepsies: interaction of genetic and acquired factors
    Berkovic, Samuel F.
    Mulley, John C.
    Scheffer, Ingrid E.
    Petrou, Steven
    [J]. TRENDS IN NEUROSCIENCES, 2006, 29 (07) : 391 - 397
  • [10] Björklund A, 2000, NOVART FDN SYMP, V231, P7